Olr80 inhibitors represent a fascinating class of chemical compounds that primarily function by targeting the Olr80 receptor, a specific type of olfactory receptor. Olfactory receptors, which are G-protein coupled receptors (GPCRs), are primarily known for their role in the detection of odor molecules, contributing to the sense of smell. However, recent research has uncovered that these receptors are also present in various non-olfactory tissues, indicating a broader range of biological roles. Olr80 inhibitors are designed to selectively bind to and modulate the activity of the Olr80 receptor, thereby influencing the signaling pathways and physiological processes associated with this receptor. The development of these inhibitors involves intricate chemical synthesis and optimization processes to achieve high specificity and potency.
The structure-activity relationship (SAR) studies of Olr80 inhibitors are critical for understanding their binding mechanisms and enhancing their efficacy. These inhibitors often feature diverse chemical scaffolds, including heterocyclic compounds, which are modified to improve receptor binding and selectivity. The binding interactions between Olr80 inhibitors and the receptor are characterized by a combination of hydrogen bonding, hydrophobic interactions, and Van der Waals forces. Advanced techniques such as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy are employed to elucidate the precise binding conformations and molecular dynamics. Additionally, computational modeling and molecular docking studies play a significant role in predicting the interaction profiles and optimizing the inhibitor design. The study of Olr80 inhibitors not only advances our understanding of olfactory receptor function beyond traditional sensory perception but also opens new avenues in chemical biology and receptor pharmacology.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor, may alter MAPK/ERK pathway, potentially affecting Olr80 signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor, could impact PI3K/AKT pathway, indirectly influencing Olr80. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Another PI3K inhibitor, possibly altering pathways that regulate Olr80. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
MEK1/2 inhibitor, might modulate MAPK/ERK signaling related to Olr80. | ||||||
MEK 162 | 606143-89-9 | sc-488879 | 10 mg | $306.00 | ||
Targets MEK1/2, potentially affecting pathways connected to Olr80. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
mTOR inhibitor, could influence signaling pathways linked to Olr80 function. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
RAF inhibitor, might impact RAF/MEK/ERK pathway influencing Olr80 activity. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $75.00 $121.00 | 33 | |
EGFR inhibitor, could affect EGFR signaling pathways related to Olr80. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $197.00 $520.00 $1093.00 | 4 | |
Multi-targeted receptor tyrosine kinase inhibitor, potentially affecting Olr80 through various pathways. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Dual EGFR and HER2/neu inhibitor, might alter pathways linked to Olr80. | ||||||